Streetbeat News

Products Services

VIGL

Vigil Neuroscience announced an update to its clinical development strategy for the IGNITE trial of iluzanebart following a Type C meeting with the FDA. The final analysis, including all patients dosed at 12 months, will be reported in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:18 am

CSIQ

Canadian Solar's subsidiary, CSI Solar, has secured a contract to provide 11 MW AC/22 MWh AC energy storage solutions for Root-Power's Coryton Energy Park project in England. Construction began in May 2024.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:15 am

W

Wayfair is planning a four-day exclusive sales event for Black Friday in July, offering up to 80% off on home products from July 26-29.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:13 am

SRE

Sempra Infrastructure, a subsidiary of Sempra, announced that Port Arthur LNG Phase 2 and Bechtel Energy have signed a fixed-price engineering, procurement, and construction contract for the Port Arthur LNG Phase 2 project in Texas.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:11 am

BRKR

Bruker has posted a bond to suspend an injunction that was affecting sales of its CosMx Spatial Molecular Imager products by its NanoString business in Germany.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:10 am

MRNS

China National Medical Products Administration has approved Marinus Pharmaceuticals' Ganaxolone oral suspension for treating epileptic seizures in patients aged two years and older with CDKL5 deficiency disorder.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:09 am

SYRA

Siyata Mobile shares are trading higher following the announcement of new orders for its SD7 handsets and related accessories, valued at over $4.5 million, from US wireless carriers.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:09 am

AGEN

Agenus announced the outcomes of its End-of-Phase-2 meeting and topline interim Phase 2 data for its BOT/BAL combination. The company has reached an agreement with the FDA on the Phase 3 dose for this combination.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:07 am

SYTA

Siyata Mobile has secured new orders for its SD7 handsets and related accessories valued at over $4.5 million from US wireless carriers.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:06 am

IONS

Ionis Pharmaceuticals has completed enrollment in the pivotal trial of Zilganersen (ION373) for treating Alexander Disease, a rare neurological disorder. Topline data are expected in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:06 am